Quest Diagnostics (DGX) Equity Average (2016 - 2025)
Quest Diagnostics (DGX) has disclosed Equity Average for 17 consecutive years, with $7.2 billion as the latest value for Q4 2025.
- Quarterly Equity Average rose 6.2% to $7.2 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $7.2 billion through Dec 2025, up 6.2% year-over-year, with the annual reading at $7.0 billion for FY2025, 6.59% up from the prior year.
- Equity Average hit $7.2 billion in Q4 2025 for Quest Diagnostics, roughly flat from $7.3 billion in the prior quarter.
- In the past five years, Equity Average ranged from a high of $7.3 billion in Q3 2025 to a low of $6.0 billion in Q1 2023.
- Historically, Equity Average has averaged $6.6 billion across 5 years, with a median of $6.4 billion in 2022.
- Biggest five-year swings in Equity Average: increased 19.39% in 2021 and later fell 6.82% in 2023.
- Year by year, Equity Average stood at $6.5 billion in 2021, then dropped by 5.52% to $6.1 billion in 2022, then grew by 4.94% to $6.4 billion in 2023, then increased by 6.36% to $6.8 billion in 2024, then rose by 6.2% to $7.2 billion in 2025.
- Business Quant data shows Equity Average for DGX at $7.2 billion in Q4 2025, $7.3 billion in Q3 2025, and $7.1 billion in Q2 2025.